California State Teachers Retirement System lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 518,947 shares of the medical equipment provider’s stock after selling 35,977 shares during the period. California State Teachers Retirement System owned 0.19% of Hologic worth $23,550,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Hologic by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after buying an additional 1,200,825 shares during the period. State Street Corp grew its stake in shares of Hologic by 1.5% in the 1st quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock valued at $540,846,000 after buying an additional 189,572 shares during the period. Capital World Investors purchased a new stake in shares of Hologic in the 2nd quarter valued at approximately $312,441,000. Victory Capital Management Inc. grew its stake in shares of Hologic by 23.7% in the 2nd quarter. Victory Capital Management Inc. now owns 5,012,352 shares of the medical equipment provider’s stock valued at $227,461,000 after buying an additional 961,528 shares during the period. Finally, Bank of Montreal Can grew its stake in shares of Hologic by 6.6% in the 2nd quarter. Bank of Montreal Can now owns 3,418,319 shares of the medical equipment provider’s stock valued at $155,123,000 after buying an additional 211,550 shares during the period. 96.38% of the stock is owned by institutional investors.

In other Hologic news, Director Lawrence M. Levy sold 9,596 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total transaction of $353,228.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the sale, the director now owns 23,810 shares of the company’s stock, valued at $955,257.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,775 shares of company stock valued at $1,175,662. 0.79% of the stock is owned by insiders.

HOLX has been the subject of several analyst reports. Royal Bank Of Canada dropped their price target on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research note on Thursday, August 3rd. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Barclays PLC dropped their price target on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a research note on Thursday, August 3rd. Finally, Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company’s stock. Hologic presently has an average rating of “Hold” and a consensus target price of $47.77.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at 36.28 on Monday. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The firm’s 50-day moving average is $37.64 and its 200-day moving average is $41.89. The firm has a market capitalization of $10.18 billion, a price-to-earnings ratio of 13.51 and a beta of 0.91.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. During the same period in the previous year, the firm earned $0.51 earnings per share. Hologic’s revenue for the quarter was up 12.4% on a year-over-year basis. Equities research analysts forecast that Hologic, Inc. will post $2.01 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/california-state-teachers-retirement-system-reduces-position-in-hologic-inc-holx/1634328.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.